EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial
      QxMD      Google Scholar   
Citation:
Br J Cancer vol 111 (6) 1065-1071
Year:
2014
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Preliminary reports from this study were presented at the Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symposium 3–7 December 2012; San Antonio, TX (abstract 850544).
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
4
Parents:
701  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821 , U10 CA180821, R01 CA-139431, CA-129949, R01 CA139431, P30 CA015083, R01 CA129949, U10 CA25224, U10 CA025224, U10 CA180888  
Corr. Author:
 
Authors:
                               
Networks:
 
Study
NCCTG-N9831
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
epidermal growth factor receptor, trastuzumab, tumour biomarker, immunofluorescence assay, breast cancer